Author: Kevin Bae
-
Prudential Financial (PRU) announces 4.2% dividend bump
The Company’s Board of Directors has authorized the repurchase of up to $1.0 billion of outstanding Common Stock during the period from January 1, 2023 through December 31, 2023. In addition, the Company declared a quarterly dividend of $1.25 per share of Common Stock, payable on March 16, 2023, to shareholders of record as of…
-
3M (MMM) bumps dividend higher by 0.67%
The 3M Board of Directors (NYSE:MMM) today declared a dividend on the company’s common stock of $1.50 per share for the first quarter of 2023. The dividend is payable March 12, 2023, to shareholders of record at the close of business on Feb. 17, 2023. 3M has paid dividends to its shareholders without interruption for more…
-
T. Rowe Price (TROW) increases dividend by 1.7%
T. Rowe Price Group (TROW), Inc. , announced today that its Board of Directors has declared a quarterly dividend of $1.22 per share payable March 30, 2023, to stockholders of record as of the close of business on March 15, 2023. The quarterly dividend rate represents a 1.7% increase over the previous quarterly dividend rate of $1.20 per share. This will mark…
-
OneMain Financial (OMF) increases dividend by 5.3%
On February 7, 2023, OneMain declared a quarterly dividend of $1.00 per share, payable on February 24, 2023, to record holders of the Company’s common stock as of the close of business on February 17, 2023. During the quarter, the Company repurchased approximately 1.6 million shares of common stock for $57 million. “We feel very…
-
Oaktree Specialty Lending (OCSL) increases dividend 1.9%
A quarterly cash distribution was declared of $0.55 per share, up 2% from $0.54 per share in the prior quarter and the eleventh consecutive quarterly distribution increase. The distribution is payable in cash on March 31, 2023 to stockholders of record on March 15, 2023. Armen Panossian, Chief Executive Officer and Chief Investment Officer, said, “We…
-
AbbVie looks to new drugs amidst increased competition for Humira
Now that its blockbuster immune-disease therapy Humira is facing lower priced competition, AbbVie is turning to a pair of next-generation successors to replenish the billions of dollars in sales that will be lost, Chief Executive Richard Gonzalez said. It is also betting on four drug approvals by the end of next year. In addition, AbbVie is lifting a self-imposed…